skip to content

Centre for Law, Medicine and Life Sciences

Faculty of Law

Nature Biotechnology has accepted a third article from an LML research group for publication. The forthcoming feature article announces empirical results about the effects of the US Supreme Court's decision in Association for Molecular Pathology v Myriad Genetics on patent practice beyond isolated DNA claims. 

The article, co-authored by Professor Mateo Aboy, Dr Cristina Crespo, Dr Kathy Liddell, Dr John Liddicoat and Mr Matt Jordan, is the third publication accepted by Nature Biotechnology in three years. It follows their 2016 paper 'Myriad's impact on gene patents', a post-Myriad empirical patent landscape analysis, and their 2017 paper 'After Myriad, what makes a gene patent claim ‘markedly different’ from nature?', which identified the types of claim amendments which successfully transformed isolated gene claims from ineligible subject matter into patent eligible inventions following Myriad.

Empirical patent studies have become a core focus of LML research, and will feature significantly in LML's contribution to the CeBIL research programme. The announcement of this publication also coincides with the conclusion of the three-year Philomathia Social Sciences Research Programme project 'Realising Genomic Medicine: Intellectual Property Issues beyond the 'Old' DNA Patent Debates.